TabsDetailsBasic DetailsDate: Monday, May 13, 2013Type: PublicationMedical Product: bupropion, smoking cessation drug, varenicline tartrateHealth Outcome(s): acute coronary occlusion without myocardial infarctionacute myocardial infarction (AMI)cardiovascular outcomeintermediate coronary syndromeunstable anginaDescription: This article describes a Mini-Sentinel modular program-based one-time rapid assessment of the risk of a composite cardiovascular outcome associated with new use of smoking cessation drugs, including varenicline and bupropion. Modular programs are adaptable standardized programs. Read More Materials: JAMA Internal Medicine, Volume 173, Issue 9, May 2013, Pages 817-819, DOI: 10.1001/jamainternmed.2013.3004Additional InformationInformationTime Period: 2006-2011Population / Cohort: All individuals 18 years of age or olderData Source(s): Mini-Sentinel Distributed Database (MSDD)Related Assessment(s): Smoking Cessation Drugs and Cardiovascular OutcomesContributorsAuthor(s): Sengwee Toh ScD; Meghan A. Baker MD, ScD; Jeffrey S. Brown PhD; Cynthia Kornegay PhD; Richard Platt MD, MSCorresponding Author: S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, USA. E-mail: darren_toh@harvardpilgrim.org
